Mineral and bone disorder and longterm survival in a chronic kidney disease grade 3b-4cohort

References

• Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–1953.
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305. (Erratum in: N Engl J Med. 2008;18(4):4).
   PubMed Web of Science ®Google Scholar
• Felsenfeld AJ, Levine BS, Rodriguez M. Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease. Semin Dial. 2015;28(6):564–577.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Rodriguez M, Ketteler M. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease? Semin Nephrol. 2014;34(2):151–163.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–S130.
   Google Scholar
• Bellorin-Font E, Vasquez-Rios G, Martin KJ. Controversies in the management of secondary hyperparathyroidism in chronic kidney disease. Curr Osteoporos Rep. 2019;17(5):333–342.
   PubMed Web of Science ®Google Scholar
• Bover J, Ureña-Torres P, Mateu S, et al. Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait? Clin Kidney J. 2020;13(4):513–521.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–S201.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36 (Erratum in: Kidney Int. 2017;92(6):1558).
   PubMed Web of Science ®Google Scholar
• Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30(9):1542–1551.
   PubMed Web of Science ®Google Scholar
• Fernández-Martín JL, Dusso A, Martínez-Camblor P, et al. Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrol Dial Transplant. 2019;34(4):673–681.
   PubMed Web of Science ®Google Scholar
• Górriz JL, Molina P, Bover J, et al. En nombre de los investigadores del estudio OSERCE. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study. Nefrología. 2013;33(1):46–60.
   PubMed Web of Science ®Google Scholar
• Molina P, Molina MD, Pallardó LM, et al. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study. J Nephrol. 2021;34(4):1189–1199.
   PubMed Web of Science ®Google Scholar
• Canzani O, De Souza N, Gadola L, Lamadrid V, Rios P, Schwedt E, Sola L, Mazzuchi N (Coordinación por Comisión Honoraria de Salud Renal). Guías de Práctica Clínica en el Diagnóstico y Tratamiento de la Enfermedad Renal Crónica. Uruguay 2013. Publicación Técnica N° 22, Fondo Nacional de Recursos, 2014. ISBN 978-9974-7679-2-8. Available from: http://www.fnr.gub.uy/sites/default/files/publicaciones/FNR_guias_practica_clinica_ERC_2013.pdf.
   Google Scholar
• Schwedt E, Solá L, Ríos PG, et al., National Renal Healthcare Program. Improving the management of chronic kidney disease in Uruguay: a National Renal Healthcare Program. Nephron Clin Pract. 2009;114(1):c47–59.
   PubMedGoogle Scholar
• Mazzuchi N, Schwedt E, Solá L, et al. Risk factors and prevention of end stage renal disease in Uruguay. Ren Fail. 2006;28(8):617–625.
   PubMed Web of Science ®Google Scholar
• Ríos-Sarro P, Sola L, Gadola L. Prevalence of CKD in Uruguay. In: García-García G, Agodoa, LY, Norris KC, editors. Chronic kidney disease in disadvantaged populations. London: Academic Press; 2017. p. 35–44.
   Google Scholar
• Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622–627.
   PubMed Web of Science ®Google Scholar
• Willis K, Cheung M, Slifer S, KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;3(1):1–9.
   Web of Science ®Google Scholar
• Schwedt E, Olascoaga A, Sánchez MF, et al. Primer consenso nacional sobre proteinuria en el diagnóstico y la evaluación de la enfermedad renal crónica en adultos. Arch Med Int. 2012;34(1):3–11.
   Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18(6):800–804.
   PubMed Web of Science ®Google Scholar
• Torregrosa JV, Bover J, Cannata Andía J, et al. Recomendaciones de la Sociedad Española de Nefrología Para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (S.E.N.-MM). Nefrología. 2011;31(Suppl 1):3–32.
   PubMed Web of Science ®Google Scholar
• Isakova T, Cai X, Lee J, et al. Longitudinal evolution of markers of mineral metabolism in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2020;75(2):235–244.
   PubMed Web of Science ®Google Scholar
• Neto R, Frazão J. Efficacy and safety of calcium carbonate in normophosphataemic patients with chronic kidney disease stages 3 and 4. Clin Kidney J. 2021;14(2):550–555.
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International. 2007;71(1):31–38.
   PubMed Web of Science ®Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–1930.
   PubMed Web of Science ®Google Scholar
• Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(16):1730–1737.
   PubMedGoogle Scholar
• Silvariño R, Rios P, Baldovinos G, et al. Is chronic kidney disease progression influenced by the type of renin-angiotensin-system blocker used? Nephron. 2019;143(2):100–107.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Ciceri P, Galassi A. Hyperphosphatemia: a novel risk factor for mortality in chronic kidney disease. Ann Transl Med. 2019;7(3):55.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Sacks F, Pfeffer M, et al. Cholesterol and recurrent events trial investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112(17):2627–2633 (Erratum in: Circulation. 2007;116(23):e556).
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Massy ZA, et al. Strategies for phosphate control in patients with CKD. Kidney Int Rep. 2019;4(8):1043–1056.
   PubMed Web of Science ®Google Scholar
• Favero C, Carriazo S, Cuarental L, et al. Phosphate, microbiota and CKD. Nutrients. 2021;13(4):1273.
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Pedagogos E, Lioufas NM, et al. A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol. 2020;31(11):2653–2666.
   PubMed Web of Science ®Google Scholar
• Melamed ML, Buttar RS, Coco M. CKD-mineral bone disorder in stage 4 and 5 CKD: what we know today? Adv Chronic Kidney Dis. 2016;23(4):262–269.
   PubMed Web of Science ®Google Scholar
• Jiménez Villodres M, García Gutiérrez G, García Frías P, et al. Fractional excretion of phosphorus and vascular calcification in stage 3 chronic kidney disease. J Investig Med. 2019;67(3):674–680.
   PubMed Web of Science ®Google Scholar
• Kovesdy C, Kuchmak O, Lu J, et al. Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease. CJASN. 2010;5(3):468–476.
   PubMed Web of Science ®Google Scholar
• Fouque D, Roth H, Darné B, et al. Achievement of 2009 and 2017 kidney disease: improving global outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease stages 4 and 5 non-dialysis patients. Clin Kidney J. 2018;11(5):710–719.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Bover J, Ureña-Torres P. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int. 2016;90(6):1184–1190.
   PubMed Web of Science ®Google Scholar
• Duranton F, Rodriguez-Ortiz ME, Duny Y, et al. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol. 2013;37(3):239–248.
   PubMed Web of Science ®Google Scholar
• Christodoulou M, Aspray TJ, Schoenmakers I. Vitamin D supplementation for patients with chronic kidney disease: a systematic review and meta-analyses of trials investigating the response to supplementation and an overview of guidelines. Calcif Tissue Int. 2021;109(2):157–178.
   PubMed Web of Science ®Google Scholar